We are beginning a series of 10 articles on 10 blue chip dividend aristocrats, some, if not all, of which are must-haves in any proper biotech portfolio. In today's article, I will cover Johnson & Johnson (JNJ), and then follow up with the following list. I will discuss pros and cons of each investment as a dividend. At the end of the series, I will sum it all up by giving an order to the stocks - best to worst as dividend stocks.
The list
| No. | Ticker | Company | Country | Market Cap | P/E | Price | Yield | Founded |
| 1 | JNJ | Johnson & Johnson | USA | 359.01B | 22.51 | 133.1 | 2.52 | 1886 |
| 2 | NVS | Novartis AG | Switzerland | 217.75B | 30.42 | 83.35 | 3.26 | 1859 |
| 3 | RHHBY | Roche | Switzerland | 217.5B | 21.52 | 31.48 | 3.26 | 1896 |
| 4 | PFE | Pfizer Inc. | USA | 196.77B | 24.22 | 33.25 | 3.85 | 1849 |
| 5 | MRK | Merck & Co., Inc. | USA | 171.76B | 33.98 | 62.38 | 3.01 | 1891 |
| 6 | SNY | Sanofi | France | 119.16B | 21.63 | 47.55 | 3.45 | 1834 |
| 7 | GSK | GlaxoSmithKline plc | United Kingdom | 95.10B | 43.2 | 38.79 | 5.13 | 1850 |
| 8 | BMY | Bristol-Myers Squibb Company | USA | 93.26B | 20.67 | 56.73 | 2.75 | 1887 |
| 9 | NVO | Novo Nordisk A/S | Denmark | 91.16B | 18.74 | 45.81 | 2.44 | 1923 |
| 10 | LLY | Eli Lilly and Company | USA | 88.93B | 35.18 | 81.15 | 2.56 | 1876 |
Source: Author
